Prescription Pad
Renin-Angiotensin-Aldosterone Inhibitors and COVID-19

https://doi.org/10.1016/j.nurpra.2020.05.007Get rights and content

Highlights

  • There is a concern that renin–angiotensin–aldosterone system (RAAS) blockers increase susceptibility to coronavirus 2019 (COVID-19).

  • There no evidence that treatment with RAAS blockers worsens the course of COVID-19.

  • Discontinuation of RAAS blockers may exacerbate cardiovascular comorbidities.

  • RAAS blockers should be continued in patients with otherwise stable conditions.

Cited by (0)

Irina Benenson, DNP, FNP, Assistant Professor, Rutgers University School of Nursing Newark, NJ. She can be reached at [email protected].

Frederick Waldron, MD, MPH, is an attending physician, Department of Emergency Medicine, Newark Beth Israel Medical Center, Newark, NJ.

In compliance with national ethical guidelines the authors report no relationships with business or industry that would pose a conflict of interest.

View Abstract